Princeton Capital Management LLC Mesoblast LTD Transaction History

Princeton Capital Management LLC

$272 Million
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$5.87 - $7.85 $1.08 Million - $1.44 Million	-183,914 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$6.69 - $9.0 $60,497 - $81,387	9,043 Added 5.17%	183,914 $1.38 Million
Q1 2021 May 12, 2021	BUY	$8.26 - $11.4 $13,695 - $18,901	1,658 Added 0.96%	174,871 $1.45 Million
Q4 2020 Feb 11, 2021	BUY	$8.21 - $18.59 $209,806 - $475,067	25,555 Added 17.31%	173,213 $1.47 Million
Q3 2020 Nov 12, 2020	BUY	$11.33 - $19.81 $103,499 - $180,964	9,135 Added 6.59%	147,658 $2.74 Million

Q2 2020 Aug 10, 2020	BUY	$4.2 - $15.45 $78,640 - $289,285	18,724 Added 15.63%	138,523 $1.58 Million
Q1 2020 May 13, 2020	BUY	$3.38 - $10.63 $20,283 - $63,790	6,001 Added 5.27%	119,799 $1.41 Million
Q4 2019 Feb 12, 2020	SELL	$5.74 - $7.42 $18,379 - $23,758	-3,202 Reduced 2.74%	113,798 $1.09 Million
Q3 2019 Nov 14, 2019	BUY	$4.68 - $7.42 $11,700 - $18,550	2,500 Added 2.18%	117,000 $811,000
Q2 2019 Aug 12, 2019	BUY	$4.67 - $5.88 $32,928 - $41,459	7,051 Added 6.56%	114,500 $608,000
Q1 2019 May 02, 2019	SELL	$4.19 - $5.25 $36,109 - $45,244	-8,618 Reduced 7.43%	107,449 $564,000
Q4 2018 Feb 13, 2019	SELL	$3.51 - $8.6 $101,902 - $249,675	-29,032 Reduced 20.01%	116,067 $478,000
Q3 2018 Nov 08, 2018	SELL	$5.75 - $8.16 $7,883 - $11,187	-1,371 Reduced 0.94%	145,099 $1.18 Million
Q2 2018 Aug 02, 2018	SELL	$5.27 - $6.21 $4,337 - $5,110	-823 Reduced 0.56%	146,470 $806,000
Q1 2018 May 03, 2018	BUY	$4.91 - $7.72 $114,260 - $179,652	23,271 Added 18.76%	147,293 $851,000
Q4 2017 Feb 12, 2018	BUY	$4.91 - $7.23 $608,948 - $896,679	124,022	124,022 $724,000

Others Institutions Holding MESO

# of Institutions

Shares Held

151K

Call Options Held

Put Options Held

View Full List

About MESOBLAST LTD

Ticker MESO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 147,316,000
Market Cap $1.12B
Description
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its ...

More about MESO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Princeton Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Princeton Capital Management LLC with notifications on news.

Account